Your browser doesn't support javascript.
loading
Observations on Glucose Excursions With the Use of a Simple Protocol for Insulin, Following Antenatal Betamethasone Administration.
Paulsen, Chané; Hall, David R; Mason, Deidré; van de Vyver, Marí; Coetzee, Ankia; Conradie, Magda.
Afiliação
  • Paulsen C; Department of Obstetrics & Gynecology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
  • Hall DR; Department of Obstetrics & Gynecology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
  • Mason D; Department of Obstetrics & Gynecology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
  • van de Vyver M; Department of Medicine, Division of Endocrinology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
  • Coetzee A; Department of Medicine, Division of Endocrinology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
  • Conradie M; Department of Medicine, Division of Endocrinology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
Front Endocrinol (Lausanne) ; 11: 592522, 2020.
Article em En | MEDLINE | ID: mdl-33519707
ABSTRACT

Aims:

Pregnant women with diabetes often require preterm delivery. Antenatal betamethasone reduces perinatal morbidity and mortality, but induces hyperglycemia. The primary objective was to observe glucose excursions and determine the preliminary safety of a protocol for subcutaneous insulin following betamethasone administration in an antenatal ward. Material and

Methods:

This retrospective study included all women with diabetes who received betamethasone due to anticipated preterm delivery. Glucose excursions were evaluated in the fasting state and 2-h postprandial. Blood glucose values ≥14mmol/L or ≤3.5mmol/L were regarded as unacceptable hyper- and hypoglycemia respectively. Events over the first 96 h were documented.

Results:

This study spanned 52 months and included fifty-nine women. Eleven episodes of defined hypoglycemia occurred in six women, all receiving insulin therapy, but none after a corrective dose of insulin. No serious hypoglycemic incident was reported. Seventeen women experienced hyperglycemic incidents almost entirely (47/56) within 48 h of betamethasone administration, most often postprandially (34/56) and in 85% of episodes, preceded by pre-prandial values >9 mmol/L (29/34). 14 (82.4%) of these women were receiving background insulin therapy. No case with gestational diabetes encountered defined hyperglycemia.

Conclusions:

This small study demonstrated preliminary safety of the protocol. Enhanced surveillance is necessary for 72 h after initiation of betamethasone.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicemia / Betametasona / Diabetes Gestacional / Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Anti-Inflamatórios Tipo de estudo: Guideline / Observational_studies Limite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: África do Sul

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicemia / Betametasona / Diabetes Gestacional / Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Anti-Inflamatórios Tipo de estudo: Guideline / Observational_studies Limite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: África do Sul